Open AccessJournal Article
Predictors of fractures in early rheumatoid arthritis.
TLDR
Three hundred ninety-five patients with rheumatoid arthritis were followed for an average of 6.7 years, and their baseline variables from the initial visit were examined for prediction of time to first fracture.Abstract:
Three hundred ninety-five patients with rheumatoid arthritis (mean age 49 years) were followed for an average of 6.7 years, and their baseline variables from the initial visit were examined for prediction of time to first fracture. Multivariate analyses identified use of corticosteroids in women and prior diagnosis of osteoporosis as important risk factors. Among patients taking 5 mg or more of prednisone, female sex strongly predicted fractures: the 5-year probability of having a fracture was 34%. Low risk groups were nonosteoporotic and consisted of men and patients taking less than 5 mg prednisone.read more
Citations
More filters
Journal ArticleDOI
Use of oral corticosteroids and risk of fractures.
T P van Staa,T P van Staa,Hubertus G. M. Leufkens,Lucien Abenhaim,Lucien Abenhaim,B. Zhang,Colin Cooper +6 more
TL;DR: The results quantify the increased fracture risk during oral corticosteroid therapy, with greater effects on the hip and spine than forearm, which has implications for the use of preventative agents against bone loss in patients at highest risk.
Journal ArticleDOI
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Kenneth G. Saag,Ronald Emkey,Thomas J. Schnitzer,Jacques P. Brown,Federico Hawkins,Stefan Goemaere,Gorm Thamsborg,Uri A. Liberman,Pierre D. Delmas,Marie Pierre Malice,Michelle Czachur,Daifotis Anastasia G +11 more
TL;DR: Two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women who were receiving glucocorticoid therapy found changes in bone density of the hip, biochemical markers of bone turnover, and the incidence of new vertebral fractures.
Journal ArticleDOI
Recommendations for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Marc C. Hochberg,Mark J. Prashker,Maria Greenwald,Rancho Mirage,Marian T. Hannan,Nancy E Lane,Stephen M. Lindsey,Daniel J. Lovell,Elizabeth A. Tindall +8 more
TL;DR: Treatment with a bisphosphonate is recommended to prevent bone loss in all men and postmenopausal women in whom long-term glucocorticoid treatment at > or =5 mg/day is being initiated, as well as in men andPost menopausal women receiving long- term glucocORTicoids in whom the BMD T-score at either the lumbar spine or the hip is below normal.
Journal ArticleDOI
Therapeutic Strategies for Rheumatoid Arthritis
TL;DR: Approaches that have resulted in markedly better clinical outcomes are considered, including early diagnosis and treatment; the advent of combinations of disease-modifying antirheumatic drugs and agents that target cytokines; and recognition and treatment of important coexisting conditions, particularly cardiovascular disease and osteoporosis.
Journal ArticleDOI
Oral corticosteroids and fracture risk: relationship to daily and cumulative doses
TL;DR: The findings suggest that the adverse skeletal effects of oral corticosteroids manifest rapidly and are related to daily dose, and Preventive measures against cortICosteroid-induced osteoporosis should be instituted as soon after the commencement of glucocorticoid therapy as possible.